Today’s steep drop is fallout from the company’s having set expectations too high for the DX-88 program in HAE. Astute posters such as iHub’s snorkel (a.k.a. Norman Klein from the Yahoo GTCB board) have asserted for some time that there was no way the FDA would entertain a BLA in this indication based on DYAX’s skimpy phase-2 program. From today’s PR, it’s clear that this view was correct.
Market Data 
Markets 
AI
